Kyntra Bio, Inc. (KYNB)vsRegeneron Pharmaceuticals Inc (REGN)
KYNB
Kyntra Bio, Inc.
$7.97
-0.06%
HEALTHCARE · Cap: $34.38M
REGN
Regeneron Pharmaceuticals Inc
$781.49
-1.48%
HEALTHCARE · Cap: $80.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 336440% more annual revenue ($15.53B vs $4.62M). KYNB leads profitability with a 3969.0% profit margin vs 27.9%. REGN earns a higher WallStSmart Score of 66/100 (B-).
KYNB
Hold46
out of 100
Grade: D+
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KYNB.
Margin of Safety
+44.4%
Fair Value
$1404.34
Current Price
$781.49
$622.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 3969 of every $100 in revenue as profit
Strong operational efficiency at 1192.0%
Revenue surging 36.5% year-over-year
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Negative free cash flow — burning cash
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : KYNB
The strongest argument for KYNB centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 3969.0% and operating margin at 1192.0%. Revenue growth of 36.5% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : KYNB
The primary concerns for KYNB are EPS Growth, Market Cap, Return on Equity.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
KYNB carries more volatility with a beta of 1.04 — expect wider price swings.
KYNB is growing revenue faster at 36.5% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (66/100 vs 46/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kyntra Bio, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is headquartered in San Francisco, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?